|
Hi SELF Family,
Tomorrow evening I go live in the members room. This is the smaller one, where I take fewer questions and go much deeper on each.
Every question tomorrow came from you. I pulled 73 questions out of the comments on the last 11 videos, clustered them by how many different people asked the same thing, and then applied one rule: it only makes the list if I can answer it from named, peer-reviewed evidence. Five cleared. Four popular ones did not, and I will tell you on air which ones and why.
Here is what we are covering.
Does a seated calf raise really replace a walk?
Sixteen of you asked a version of this, which makes it the most-asked question this room has sent me all year. The 52 percent figure people quote is real, and it comes from a 2022 iScience paper on the soleus muscle. The walking evidence is separate: a 2022 meta-analysis in Sports Medicine pooling 7 randomized crossover trials. Both numbers are true. They were produced under very different conditions, and the conditions are what tell you which one belongs in your afternoon. I will give you a straight answer on which to do, and tell you plainly where I am reading past the evidence.
Does the daily multivitamin actually do anything?
Several of you asked about the COSMOS trial by name, which tells me this room reads primary sources. It randomized 21,442 adults aged 60 and older. The pooled cognitive analysis favored the multivitamin, and the authors describe the size of the effect as roughly two years less cognitive aging. I will also show you the parts the press coverage left out, including how small the effect actually is and who it was measured in.
Can drinking more water slow polycystic kidney disease?
The mechanism behind this question is correct, which is what makes it a good question. Vasopressin does drive cyst growth, and that is exactly why tolvaptan works. So it was tested: 184 adults, randomized, followed for three years. I will show you what it found, and the two details inside the trial that change how much weight you should put on the result.
How do you eat enough protein after 60 when you also have kidney disease?
This was the most emotionally loaded cluster of the month. One of you wrote that it seems impossible, and asked whether that was wrong. I am going to do the arithmetic with you on screen, because the guideline number and the muscle-building number genuinely collide and the collision does not resolve neatly. Then I am going to read you the sentence in the KDIGO 2024 guideline that anticipates exactly this problem. It is in print, it is numbered, and most people living with kidney disease have never had it read to them.
Are you on every kidney-protecting medicine you qualify for?
Kidney protection used to be one thing. In about six years it became four, and the trials arrived one at a time, which means a lot of people were started on the first pillar in an era when the other three did not exist yet, and nobody circled back. I will walk all four, name the trial behind each, and give you one sentence to say at your next appointment. Not a drug name. A sentence about your own numbers, which is a harder question for anyone to wave off.
Plus, what moved in the research this month.
On July 30, JAMA published a randomized trial of 784 adults having elective cardiac surgery, testing whether four doses of a common kidney drug could protect them from acute kidney injury. The result is striking enough that I want to put the labels on it myself before it turns into a headline. This changes nothing you should do tomorrow, and it is worth three minutes of your time anyway.
| 
